Literature DB >> 25721040

CD30: seeing is not always believing.

Kristie A Blum1.   

Abstract

Although most investigators are well aware of the incredible success of brentuximab vedotin in the treatment of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jacobsen and colleagues in this issue of Blood demonstrates surprising activity of this agent in patients with B-cell non-Hodgkin lymphoma (NHL).

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25721040     DOI： 10.1182/blood-2015-01-622480

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  4 in total

1.  Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Authors:  Edward Abadir; Pablo A Silveira; Robin E Gasiorowski; Murari Ramesh; Adelina Romano; Ahmed H Mekkawy; Tsun-Ho Lo; Karieshma Kabani; Sarah Sutherland; Geoffrey A Pietersz; P Joy Ho; Christian E Bryant; Stephen R Larsen; Georgina J Clark
Journal:  Blood Adv       Date:  2020-04-14

2.  The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma.

Authors:  I-Hsiao Chung; Pei-Hsuan Lu; Yang-Hsiang Lin; Ming-Ming Tsai; Yun-Wen Lin; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

Review 3.  Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.

Authors:  Boyu Hu; Yasuhiro Oki
Journal:  Front Oncol       Date:  2018-04-30       Impact factor: 6.244

4.  The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma.

Authors:  Po-Shuan Huang; I-Hsiao Chung; Yang-Hsiang Lin; Tzu-Kang Lin; Wei-Jan Chen; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2018-05-14       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.